← Eichor
Study identifier: NCT05737732 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Ambient Light Multiple Myeloma Study

Condition: Multiple Myeloma  ·  Sponsor: Icahn School of Medicine at Mount Sinai

PhaseNA
Planned participants200
Who can joinAll sexes, 21 Years to no upper limit
Healthy volunteersNo

About this study

The aim of this multi-site randomized control trial will be is to assess the impact Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients undergoing Autologous Stem Cell Transplantation. To achieve this aim, 200 multiple myeloma patients will receive one of two different light-treatments that are designed to promote circadian rhythm alignment. While receiving these light treatments, participants' sleep efficiency, urine melatonin levels, blood inflammatory cytokine levels and symptoms will be assessed over a 2-month period.

This description comes directly from the study's public registry record.

Talk to the study team

Barbara Plitnick, BSN  ·  518 242-4603  ·  Barbara.Plitnick@mountsinai.org

Mariana Figueiro, PhD  ·  518-366-9306  ·  Mariana.Figueiro@mountsinai.org

Always discuss trial participation with your own doctor first.

Locations (2)

Icahn Schoool of Medicine at Mount SinaiNew York, New York, United StatesRecruiting
Memorial Sloan Kettering Cancer CenterNew York, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05737732